Hims & Hers Strikes GLP-1 Deal with Lilly, Stock Rallies
TREE NEWS reports: Hims & Hers Health has reached an agreement with Eli Lilly that will allow the telehealth company to continue offering GLP-1 weight-loss medications while ceasing its compounding of Lilly’s blockbuster drug Zepbound. The deal, announced Tuesday, sent Hims & Hers shares sharply higher as investors bet the company can maintain its fast-growing weight-loss business without running afoul of regulators or the brand-name manufacturer.
Under the terms, Hims & Hers will stop compounding tirzepatide, the active ingredient in Zepbound, and will instead direct patients toward Lilly’s FDA-approved product. The company had been selling compounded versions of GLP-1 drugs at lower prices, a practice that drew scrutiny from the FDA and from Lilly itself. The agreement removes a major legal and regulatory overhang for Hims & Hers, which has seen its stock swing wildly on news related to GLP-1 compounding.
Market Implications
The immediate impact is a relief rally in Hims & Hers shares, which had been under pressure as regulators moved to crack down on compounded GLP-1s. Investors had feared that losing the ability to sell compounded versions would gut the company’s weight-loss offering. The deal with Lilly suggests a negotiated path forward, potentially preserving a revenue stream that has become central to Hims & Hers’ growth story.
For Lilly, the agreement is a win in its effort to control the distribution of its intellectual property while expanding patient access. It also signals a willingness to work with telehealth platforms rather than solely litigate against them. The move could set a template for other telehealth companies that have been compounding GLP-1 drugs.
Broader market impact may be more muted. The GLP-1 space is dominated by Lilly and Novo Nordisk, and the deal does not change the fundamental competitive dynamics. However, it does highlight the growing importance of telehealth as a distribution channel for weight-loss drugs, a trend that could benefit both brand manufacturers and platforms that can partner with them.
In the bond market, the news is unlikely to move yields. For crypto, there is no direct read-through. Commodities could see minor effects if compounding demand for active pharmaceutical ingredients shifts, but the scale is small relative to overall GLP-1 production.
Key Takeaways for Investors
- Hims & Hers shares rallied on relief that the company can continue participating in the GLP-1 market under a negotiated agreement.
- The deal reduces regulatory risk for Hims & Hers and may serve as a model for other telehealth providers.
- Lilly strengthens control over its franchise while gaining a new patient-acquisition channel.
- Investors should watch for further FDA action on compounding and for how Hims & Hers replaces compounded revenue with branded offerings.
- The broader GLP-1 duopoly remains intact, with Lilly and Novo Nordisk still dominating the market.
